Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve blood glucose control when used with diet and exercise.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets through established distribution networks.

Jazeta, a DPP‑4 inhibitor, is used in the therapeutic management of type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): lowers HbA1c and fasting plasma glucose when added to diet and exercise. - Type 2 diabetes mellitus (combination therapy): improves glycemic control when combined with metformin or other oral antidiabetics. - Type 2 diabetes mellitus (adjunct to insulin): reduces insulin requirement and assists in achieving target glucose levels.

Sitagliptin Hydrochloride may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Upper respiratory tract infection: mild nasal congestion, sore throat or cough. - Headache: transient mild to moderate pain. - Nasopharyngitis: inflammation of the nasal passages and throat. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity reactions: skin rash, angioedema or anaphylaxis. - Acute renal failure: sudden decrease in kidney function, especially in patients with pre‑existing renal impairment.

When prescribing or dispensing Jazeta, several precautionary measures should be observed to ensure patient safety. - Renal function assessment: evaluate creatinine clearance before initiating therapy and adjust dose if necessary. - Hepatic impairment: use with caution in patients with moderate liver disease and monitor liver enzymes. - Cardiovascular risk: monitor for signs of heart failure, especially in patients with existing cardiac conditions. - Concomitant medications: review all current drugs for potential interactions that may affect glucose control. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 or CYP2C8 inhibitors (e.g., ketoconazole, gemfibrozil): may increase sitagliptin plasma concentrations. - Insulin or sulfonylureas: combined use can heighten risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may affect glucose levels; monitor blood sugar. - Rifampin: may reduce sitagliptin exposure; consider dose adjustment. - Digoxin: potential increase in digoxin levels; check therapeutic range.